Molnupiravir (Lagevrio®). HTA ID: 21060

Assessment Status Rapid Review Complete
HTA ID 21060
Drug Molnupiravir
Brand Lagevrio®
Indication For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Assessment Process
Rapid review commissioned 30/11/2021
Rapid review completed 24/12/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of molnupiravir compared with the current standard of care on the basis of the proposed price.